New weight loss injections on the NHS: what's changed and what it means for you

Step 1: understand which medicines we're talking about

The two injections at the centre of the NHS rollout are tirzepatide, sold as Mounjaro by Eli Lilly, and semaglutide, sold as Wegovy by Novo Nordisk. They work differently at a biological level (tirzepatide activates two gut-hormone receptors (GIP and GLP-1), while semaglutide targets one (GLP-1)) but both slow gastric emptying, reduce appetite, and support meaningful weight reduction when used alongside a reduced-calorie diet and increased activity. They are not slimming pills and they are not the same as Ozempic, which is semaglutide licensed for type 2 diabetes, not weight management. The NHS medicines page for tirzepatide covers what the medicine is, how it's given, and its common side effects in plain language, a good first read before any consultation.

If you've landed on this page feeling frustrated by the gap between what you've read in the news and what your GP has actually been able to offer, that's entirely understandable. If you're unsure where to begin, our guide on how to get the new weight loss injection walks through the process from the very first step. The rollout is real, but it is gradual by design.

Step 2: find out whether you currently meet the NHS criteria

NHS access to tirzepatide follows NICE's appraisal TA1026, which recommends it for adults with a BMI of 35 or above plus at least one weight-related condition, though lower BMI thresholds apply for South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean backgrounds under UK guidance. The NHS rollout in England is phased. From June 2025, those with a BMI of 40 or above alongside four or more of five specific conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes) became eligible. From around June 2026, that opened to BMI 35–39.9 with four or more of those conditions. A further expansion to BMI 40 or above with three conditions is expected around March 2027. Every NHS patient must also take part in wraparound diet and activity support, qualifying on paper doesn't guarantee immediate access, and availability still varies by area and GP practice. If you're wondering whether you can get weight loss injections on the NHS given your own circumstances, that page sets out eligibility by cohort in plain terms. You can also explore the full picture of how weight loss injections work on the NHS for a clearer breakdown of eligibility by cohort.

Wegovy has a separate NHS route: it is recommended by NICE (TA875) for use within specialist weight management services, for a maximum of two years. Waiting lists for those services remain long in many parts of England. For a closer look at what the new NHS injection for weight loss involves, including how Wegovy fits into the specialist service pathway, that page covers the detail. You can also find a thorough overview of the weight loss injection NHS provision, including how the two medicines sit within the broader rollout.

Step 3: if you don't meet NHS criteria yet, understand your options

Many people are clinically suitable for one of these medicines (by BMI and by the presence of a weight-related condition) but fall just outside the current NHS phase, or are waiting months for an appointment. Private treatment through a regulated pharmacy is the alternative route. It requires no NHS referral and no waiting list, but it does still require a proper clinical assessment. A GPhC-registered pharmacy will carry out that assessment through a consultation, verify your identity and weight, and only issue a prescription if a clinician judges it appropriate. For context on what private treatment typically costs, the weight loss injection pricing page sets out what the market looks like honestly, including what's driven prices up since Eli Lilly revised its UK list price in September 2025. At nume, a named prescriber (not automated software) reads every consultation the same day it arrives. There are no subscriptions and no hidden fees: one price covers the consultation, prescription, and free next-working-day tracked delivery. You can read more about how we're structured as a service and verify our GPhC registration number (9012878) independently at the GPhC's register.

Step 4: know what to expect once treatment begins

Whichever route you take, these are long-term medicines, not short courses. Treatment starts at a low dose (2.5mg for tirzepatide) and the prescriber increases it gradually, typically in four-week steps, to the dose that works best for you. The most common side effects are gastrointestinal: nausea, loose stools, constipation, and heartburn are all reported, usually peaking after a dose increase before settling. Urgent signs to know about include severe stomach pain that reaches the back (which can indicate pancreatitis), gallbladder symptoms, and signs of dehydration from persistent vomiting. Any suspected side effect can be reported at the MHRA's Yellow Card scheme, patients can submit reports directly, not just clinicians. If you want to explore all options beyond these two injections, including the newly approved oral semaglutide tablet and other approaches, the treatment overview page is a reasonable next step. When you're ready to speak to a prescriber about your own situation, start a free consultation with our clinical team.